Drug profile · INN
oportuzumab monatox
OPORTUZUMAB MONATOX DLRC PHARMA SERVICES
oportuzumab monatox (OPORTUZUMAB MONATOX DLRC PHARMA SERVICES) is a epithelial cell adhesion molecule binding agent.
EMA: application withdrawn Antineoplastic and immunomodulating agents (L01) L01FX06
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — oportuzumab monatox
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.83
Quick answer
oportuzumab monatox (OPORTUZUMAB MONATOX DLRC PHARMA SERVICES) is a epithelial cell adhesion molecule binding agent.
Key facts
INN oportuzumab monatox
Brand OPORTUZUMAB MONATOX DLRC PHARMA SERVICES
Mechanism Epithelial cell adhesion molecule binding agent
Target Elongation factor 2
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01FX06
Mechanism of action
Epithelial cell adhesion molecule binding agent
Primary target: Elongation factor 2
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | application withdrawn | — |
Related & competitor drugs
Frequently asked questions
What is oportuzumab monatox?
oportuzumab monatox (OPORTUZUMAB MONATOX DLRC PHARMA SERVICES) is a epithelial cell adhesion molecule binding agent.
What is the brand name for oportuzumab monatox?
OPORTUZUMAB MONATOX DLRC PHARMA SERVICES is a marketed brand name for oportuzumab monatox. Check FDA Drugs@FDA for the current US label holder and prescribing information.